1,045 results match your criteria Lupus Erythematosus Drug-Induced


[Proximal myopathy and fulminant heart failure in a 57 year-old female patient with lupus erythematosus].

Internist (Berl) 2020 Jun 5. Epub 2020 Jun 5.

Herzzentrum Dresden, Universitätsklinik, Klinik für Innere Medizin und Kardiologie, Technische Universität Dresden, Dresden, Deutschland.

A case report is presented of fulminant hydroxychloroquine-induced cardiomyopathy in a 57 year-old female patient with a long history of systemic lupus erythematosus. Diagnosis was established based on clinical findings, imaging (echocardiography and cardiac magnetic resonance imaging) as well as endomyocardial biopsy. Despite immediate discontinuation of the medication, the patient died from heart failure within a few days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-020-00820-1DOI Listing

Herbal medication triggering lupus nephritis - a case report.

BMC Complement Med Ther 2020 Jun 2;20(1):163. Epub 2020 Jun 2.

Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, 43400, Malaysia.

Background: Herbal medication is widely used in our region as a mode of alternative medicine. Its contents and combinations are often modified to suit the needs of different populations. These products are said to boost the immune system and may serve as a protective measure against many diseases including Systemic Lupus Erythematosus (SLE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12906-020-02971-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268707PMC

Discoid Lupus Erythematosus Lesions Associated with Systemic Fluorouracil Agents: A Case Report and Review.

Authors:
Philip R Cohen

Cureus 2020 Apr 25;12(4):e7828. Epub 2020 Apr 25.

Dermatology, San Diego Family Dermatology, National City, USA.

Systemic fluorouracil agents include not only 5-fluorouracil (5FU), but also capecitabine, tegafur, and uracil/tegafur (UFT). Systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE), and discoid lupus erythematosus (DLE) are subtypes of lupus erythematosus; drug-induced lupus erythematosus can also present in each of these subtypes. This report describes the case of a 65-year-old woman with systemic 5FU-induced DLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249746PMC

Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine

Orv Hetil 2020 04 1;161(17):689-691. Epub 2020 Apr 1.

Uzsoki Utcai Kórház, Budapest, Uzsoki u. 29-41., 1145.

Hydroxychloroquine is an immunomodulatory drug that has been used to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis. The authors conclude the proarrhytmic effects of hydroxychloroquine and the most important signs of drug-induced long QT syndrome. This article is especially relevant and timely due to the more frequent (currently not evidence-based) use of the drug during the 2019–2020 coronavirus pandemic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1556/650.2020.31817DOI Listing

Cutaneous Lupus Erythematosus: Progress and Challenges.

Curr Allergy Asthma Rep 2020 Apr 4;20(5):12. Epub 2020 Apr 4.

Department of Dermatology, Duke University, Durham, NC, 27710, USA.

Purpose Of Review: The review provides an update on the diagnosis, pathogenesis, and treatment of cutaneous lupus erythematosus (CLE).

Recent Findings: Diagnostic challenges exist in better defining CLE as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11882-020-00906-8DOI Listing

Discoid drug-induced lupus erythematosus induced by antitumor necrosis factor agents is a very rare subtype of cutaneous lupus: Three cases and literature review.

Dermatol Ther 2020 May 20;33(3):e13364. Epub 2020 Apr 20.

Faculté de Médecine Sorbonne Université, AP-HP, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13364DOI Listing

Hemodynamic Collapse Following Therapeutic Plasma Exchange in a Patient Receiving an Angiotensin Receptor Blocker.

Cureus 2020 Feb 18;12(2):e7028. Epub 2020 Feb 18.

Medicine, Upstate Medical University, Syracuse, USA.

Therapeutic plasma exchange (TPE) is a procedure for removal of plasma and its components while leaving behind cellular elements via an apheresis device. It is used in multiple conditions one among which is systemic lupus erythematosus (SLE). Adverse reactions from TPE range from mild hypotension and fever to life-threatening cardiovascular compromise. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081960PMC
February 2020

Acute interstitial nephritis and drug-induced systemic lupus erythematosus due to chlorthalidone and amiodarone: A case report.

SAGE Open Med Case Rep 2020 1;8:2050313X20910029. Epub 2020 Mar 1.

Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Drug-induced lupus erythematosus has features distinct from primary systemic lupus erythematosus. It can occur with a wide variety of agents that result in the generation of anti-histone or other types of antibodies. Systemic manifestations of drug-induced systemic lupus erythematosus may include renal dysfunction due to circulating immune complexes or due to other immune reactions to the culprit medication(s). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X20910029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052449PMC

Analysis of clinical characteristics of drug-induced cutaneous lupus erythematosus in men.

J Am Acad Dermatol 2020 Mar 7. Epub 2020 Mar 7.

Department of Dermatology, Duke University, Durham, North Carolina. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.03.002DOI Listing

Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review.

J Cutan Pathol 2020 Jul 13;47(7):654-658. Epub 2020 Mar 13.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an uncommon but well-described phenomenon, most often seen in association with antihypertensives and antifungal medications. In recent years, rare reports of DI-SCLE have been described in patients being treated with targeted therapies. Herein, we describe a case of DI-SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13673DOI Listing

Cardiac Arrhythmias in Autoimmune Diseases.

Circ J 2020 Apr 26;84(5):685-694. Epub 2020 Feb 26.

1st Chair and Department of Cardiology, Medical University of Warsaw.

Autoimmune diseases (ADs) affect approximately 10% of the world's population. Because ADs are frequently systemic disorders, cardiac involvement is common. In this review we focus on typical arrhythmias and their pathogenesis, arrhythmia-associated mortality, and possible treatment options among selected ADs (sarcoidosis, systemic lupus erythematosus, scleroderma, type 1 diabetes, Graves' disease, rheumatoid arthritis, ankylosing spondylitis [AS], psoriasis, celiac disease [CD], and inflammatory bowel disease [IBD]). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1253/circj.CJ-19-0705DOI Listing

The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review.

Expert Opin Drug Metab Toxicol 2020 Feb 24;16(2):111-123. Epub 2020 Feb 24.

Amsterdam UMC, Department of Gastroenterology and Hepatology, VU University Medical Center, AG&M Research Institute, Amsterdam, Netherlands.

: In the 1950s, thioguanine (TG), a thiopurine-derivative together with azathioprine (AZA) and mercaptopurine (MP), were developed for the treatment of childhood leukemia. Over the years, the use of TG was also explored for other, mainly immune-mediated and inflammatory, diseases such as in the field of dermatology and rheumatology (. psoriasis, systemic lupus erythematosus (SLE)) and gastroenterology and hepatology (. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2020.1719996DOI Listing
February 2020

Drug-induced anti-Ro positive subacute cutaneous lupus in a man treated with olmesartan.

Dermatol Online J 2019 Dec 15;25(12). Epub 2019 Dec 15.

Hospital Corporation of America/University of South Florida Morsani College of Medicine Graduate Medical Education: Department of Dermatology, Largo Medical Center Program, Largo, FL.

A 66-year-old man presented to the outpatient dermatology clinic with a chief complaint of a pruritic rash on his upper trunk and proximal upper extremities, which had been present for three weeks. Upon examination, he was found to have an erythematous, annular, and polycyclic eruption on the chest, upper back, and proximal extremities. A clinical diagnosis of subacute cutaneous lupus erythematosus (SCLE) was made. Read More

View Article

Download full-text PDF

Source
December 2019

Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature.

Dermatol Online J 2019 Nov 15;25(11). Epub 2019 Nov 15.

Department of Dermatology, University of California San Diego, La Jolla, CA.

Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common subtype of drug-induced systemic lupus erythematosus and has been associated with more than 100 drugs. It presents weeks to months after initiation of the culprit medication. The eruption is typically in a photodistribution and it is marked by positive serology to anti-Ro (SSA) antibody. Read More

View Article

Download full-text PDF

Source
November 2019

Severe hydralazine-induced lupus presenting as systemic lupus erythematosus.

Lupus 2020 Apr 10;29(5):509-513. Epub 2020 Feb 10.

Department of Internal Medicine, Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, USA.

Despite its long history of untoward side effects of a systemic autoimmune disease, drug-induced lupus can be difficult to recognize because of the disconnect between chronic drug usage and onset of symptoms. In this case, the patient was treated with hydralazine for two years when symptoms were initially reported, but a diagnosis of hydralazine-induced lupus was not considered for another half year. Despite treatment with steroidal and nonsteroidal anti-inflammatory medications during this period, rheumatologic symptoms and signs continued to deteriorate, consistent with the diagnosis of systemic lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320906265DOI Listing

Subacute cutaneous lupus erythematosus with a possible paraneoplastic association with melanoma.

Authors:
Jesse Hirner

BMJ Case Rep 2019 Nov 28;12(11). Epub 2019 Nov 28.

Dermatology, University of Missouri, Columbia, Missouri, USA

A 52-year-old man was referred to our dermatology clinic for a diagnosis of melanoma. At the time, his melanoma was excised he developed an annular, polycyclic, scaling eruption consistent with subacute cutaneous lupus erythematosus (SCLE). Skin biopsy and laboratory evaluation confirmed this diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-230558DOI Listing
November 2019

Cutaneous lupus erythematosus induced by drugs - novel insights.

Expert Rev Clin Pharmacol 2020 Jan 2;13(1):35-42. Epub 2019 Dec 2.

Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA.

: There is a growing list of drugs implicated in inducing both subacute and chronic forms of cutaneous lupus erythematosus. It is important to recognize these drugs in order to quickly treat patients with drug induced disease.: This paper reviews the current literature describing drugs implicated in causing cutaneous lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2020.1698290DOI Listing
January 2020

Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification.

Sci Rep 2019 10 29;9(1):15502. Epub 2019 Oct 29.

Centro de Genómica e Investigaciones Oncológicas Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain.

Systemic lupus erythematosus (SLE) is a heterogeneous disease with unpredictable patterns of activity. Patients with similar activity levels may have different prognosis and molecular abnormalities. In this study, we aimed to measure the main differences in drug-induced gene expression signatures across SLE patients and to evaluate the potential for clinical data to build a machine learning classifier able to predict the SLE subset for individual patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-51616-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820741PMC
October 2019

[Drug-induced Sweet's syndrome related to hydroxychloroquine: About 2 cases].

Rev Med Interne 2020 Apr 17;41(4):289-292. Epub 2019 Sep 17.

Service de dermatologie, groupe hospitalier du Havre, 29, avenue Pierre-Mendès, 76290 Montivilliers, France.

Introduction: Hydroxychloroquine is widely prescribed in systemic lupus erythematosus. Dermatologic adverse drug reactions are rare but can mimic a disease specific manifestation of lupus. Exceptionally, Sweet's syndrome, or acute febrile neutrophilic dermatosis, may be drug-induced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revmed.2019.08.010DOI Listing
April 2020
3 Reads

Clinical Characteristics of Hydralazine-induced Lupus.

Cureus 2019 Jun 25;11(6):e4996. Epub 2019 Jun 25.

Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, USA.

Introduction The use of hydralazine has been associated with the development of lupus erythematosus and lupus-like syndromes. We performed this retrospective study to identify clinical characteristics of individuals who developed hydralazine-induced lupus. Material and methods We performed a single-center retrospective review of seven individuals who had a diagnosis of hydralazine-induced lupus by International Classification of Diseases, Ninth Revision (ICD9) code and were on hydralazine prior to their diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.4996DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707822PMC
June 2019
4 Reads

Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.

Biomed Res Int 2019 18;2019:8142368. Epub 2019 Jul 18.

Department of Dermatology, University of Rzeszow, ul. Fryderyka Szopena 2, 35-055 Rzeszow, Poland.

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting multiple organ systems that runs an unpredictable course and may present with a wide variety of clinical manifestations. Advances in treatment over the last decades, such as use of corticosteroids and conventional immunosuppressive drugs, have improved life expectancy of SLE sufferers. Unfortunately, in many cases effective management of SLE is still related to severe drug-induced toxicity and contributes to organ function deterioration and infective complications, particularly among patients with refractory disease and/or lupus nephritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8142368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668536PMC
January 2020
4 Reads

Fulminant Type 1 Diabetes Mellitus Caused by Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): A Case Report and Review of the Literature.

Front Endocrinol (Lausanne) 2019 16;10:474. Epub 2019 Jul 16.

Department of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, China.

Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS) is a rare, severe cutaneous adverse drug reaction characterized by fever, skin rashes, lymphadenopathy, leukocytosis with eosinophilia, and/or atypical lymphocytosis, and multiple visceral organ involvement. Moreover, patients with DRESS are at risk of developing autoimmune diseases including thyroiditis, diabetes mellitus (DM), and systemic lupus erythematosus (SLE), etc. several weeks or months after the initial resolution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2019.00474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646467PMC
July 2019
15 Reads

Aseptic meningitis.

Rev Neurol (Paris) 2019 Sep - Oct;175(7-8):475-480. Epub 2019 Jul 30.

Service de maladies infectieuses et réanimation médicale, CHU de Pontchaillou, rue Le Guilloux, 35033 Rennes Cedex, France.

Aseptic meningitis is defined as meningeal inflammation - i.e. cerebrospinal fluid (CSF) pleocytosis≥5 cells/mm - not related to an infectious process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2019.07.005DOI Listing
February 2020
8 Reads

Clustering of immune-mediated diseases in sarcoidosis.

Curr Opin Pulm Med 2019 09;25(5):539-553

Department of Pulmonology, St Antonius ILD Center of Excellence, St Antonius Hospital, Nieuwegein.

Purpose Of Review: Sarcoidosis is an immune-mediated disease of unknown cause. Immune-mediated diseases appear to cluster in patients and in families. We review what is known on this topic for sarcoidosis, and what factors may underlie disease clustering. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCP.0000000000000598DOI Listing
September 2019
5 Reads

Rowell's Syndrome Triggered by Omeprazole.

Acta Dermatovenerol Croat 2019 Jun;27(2):124-126

Lyubomir Dourmishev MD, PhD, Department of Dermatology and Venereology, Medical University - Sofia, Bulgaria, 1st Georgi Sofiiski Blvd,. 1431 Sofia, Bulgaria.

Dear Editor, Rowell's syndrome is a rare disease, characterized by the appearance of erythema multiforme (EM)-like lesions in patients with lupus erythematosus. It was initially reported by Rowell (1) in 1963 and its existence as a separate clinical entity is currently under debate (2,3). A few cases may have been induced by drugs such as systemic antimycotics, antibiotics, anticonvulsants, and more recently proton pump inhibitors (PPIs). Read More

View Article

Download full-text PDF

Source
June 2019
7 Reads
0.581 Impact Factor

Mimickers of neuropsychiatric manifestations in systemic lupus erythematosus.

Best Pract Res Clin Rheumatol 2018 10 22;32(5):623-639. Epub 2019 Feb 22.

Laboratory of Autoimmune Diseases, School of Medical Science, University of Campinas, Brazil; Rheumatology Unit, Department of Medicine, School of Medical Science, University of Campinas, Brazil. Electronic address:

Systemic lupus erythematosus (SLE), presenting with new onset or worsening neuropsychiatric (NP) symptoms, is a challenge in clinical practice. Mimickers such as infections, drug-induced side effects, metabolic abnormalities, malignancies, and alcohol-related disorders have to be excluded, before attributing the manifestations to disease activity. Proper diagnosis is essential to guide adequate management and reduce morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.berh.2019.01.020DOI Listing
October 2018
16 Reads

Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?

Ann Rheum Dis 2019 Jun 12. Epub 2019 Jun 12.

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2019-215819DOI Listing
June 2019
5 Reads

Pulmonary Complications of Systemic Lupus Erythematosus.

Semin Respir Crit Care Med 2019 04 28;40(2):227-234. Epub 2019 May 28.

Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by the production of pathogenic autoantibodies and immune complexes and is responsible for significant morbidity and mortality through a wide range of clinical manifestations which can affect almost any organ. Pulmonary involvement is prevalent and seen in 50 to 70% of SLE patients and may even be the presenting feature in 4 to 5% of patients. By 10 years postdiagnosis, 12% will have accumulated an element of permanent lung damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1685537DOI Listing
April 2019
11 Reads

[Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus].

Brain Nerve 2019 May;71(5):493-505

Neurology, Kouhoukai Takagi Hospital.

Here, progressive multifocal leukoencephalopathy (PML) and PML in systemic lupus erythematosus (SLE) are reviewed. Disease-modifying therapy (DMT) associated PML is an emerging condition, particularly in multiple sclerosis patients. Although PML is a rare adverse event in SLE, we should consider development of PML more carefully in not only conventional drug-induced PML but also DMT associated PML during SLE treatment in the era of DMT associated PML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416201301DOI Listing
May 2019
4 Reads

Drug-induced acute eosinophilic pneumonia due to hydroxychloroquine in a chilblain lupus patient.

J Dermatol 2019 10 3;46(10):e356-e357. Epub 2019 May 3.

Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14905DOI Listing
October 2019

Indications for bone marrow examinations in rheumatology.

Rheumatol Int 2019 07 30;39(7):1221-1228. Epub 2019 Apr 30.

Division of Rheumatology, Department of Internal Medicine, School of Medicine, Eskişehir Osmangazi University, 26480, Eskisehir, Turkey.

Hematologic involvement or hematologic malignancies are frequently encountered during the course of rheumatic diseases. Bone marrow (BM) aspiration and/or biopsy examinations may have a diagnostic role in explaining hematologic findings detected in rheumatology clinical practice. Our aim was to describe the indications for BM examinations and to share our BM aspiration/biopsy results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-019-04312-wDOI Listing
July 2019
21 Reads

Lichen Sclerosus on the Sites of Striae Distensae and a Surgical Scar in a Patient with Coexistent Morphea.

Acta Dermatovenerol Croat 2019 Mar;27(1):44-46

Sevkiye Copur, MD, Department of Dermatology & Venereology, Istanbul University, Istanbul Medical Faculty , Millet Street (Caddesi), 34093 Capa , Istanbul, Turkey;

Lichen sclerosus (LS), also known as lichen sclerosus et atrophicus, is a chronic inflammatory mucocutaneous disease affecting the genital and/or extragenital areas. Although LS usually occurs alone, its coexistence in morphea patients has been reported in 5.7% and 38. Read More

View Article

Download full-text PDF

Source
March 2019
15 Reads

MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus.

Front Immunol 2019 22;10:538. Epub 2019 Mar 22.

Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Systemic Lupus Erythematosus (SLE) is a common and devastating autoimmune disease, characterized by a dysregulated adaptive immune response against intracellular antigens, which involves both autoreactive T and B cells. In SLE, mainly intracellular autoantigens generate autoantibodies and these assemble into immune complexes and activate the classical pathway of the complement system enhancing inflammation. Matrix metalloproteinase-9 (MMP-9) levels have been investigated in the serum of SLE patients and in control subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440319PMC
March 2019
6 Reads

An intriguing case of anemia and renal failure.

Proc (Bayl Univ Med Cent) 2019 Jan 24;32(1):78-79. Epub 2019 Jan 24.

Division of Nephrology, University of Oklahoma-TulsaTulsaOklahoma.

Hydralazine-induced vasculitis is an established autoimmune entity but widely underdiagnosed despite its initial description in 1953. Hydralazine-induced lupus occurs in 5% to 10% of patients and is characterized by fever, arthralgias, rash, anemia, leukopenia, and positive antinuclear antibodies. Renal involvement is rare in drug-induced systemic lupus erythematosus but can occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08998280.2018.1540824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442904PMC
January 2019
11 Reads

Acute myocardial infarction and renal dysfunction due to chronic extreme anemia (hemoglobin 2.5 g/dL) in immune thrombocytopenia.

Proc (Bayl Univ Med Cent) 2018 Oct 23;31(4):508-510. Epub 2018 Oct 23.

Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at HoustonHoustonTexas.

Immune thrombocytopenic purpura (ITP) is an acquired thrombocytopenia where autoantibodies are generated against platelet antigens. Primary ITP is often idiopathic, whereas secondary ITP has many potential causes, including drug induced, infection related (human immunodeficiency virus, hepatitis C), leukemias, or autoimmune such as systemic lupus erythematosus. ITP is a common cause of thrombocytopenia in asymptomatic individuals, where evidence of bleeding may be minor or absent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08998280.2018.1499317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413974PMC
October 2018
11 Reads

Successful clozapine rechallenge in a patient with suspected drug induced lupus.

BMJ Case Rep 2019 Apr 3;12(4). Epub 2019 Apr 3.

Department of Psychiatry, Welland Centre, Northamptonshire, UK.

Clozapine is the most effective treatment for patients with refractory schizophrenia. Clozapine is also associated with serious and potentially lethal side effects including drug induced lupus (DIL). There have been four previous published case reports describing clozapine inducing a lupus-like syndrome including one previous case where a clozapine rechallenge was attempted without success. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-228574DOI Listing
April 2019
8 Reads

Rheumatologic Diseases and the Liver.

Clin Liver Dis 2019 05 8;23(2):247-261. Epub 2019 Mar 8.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Howard University Hospital and College of Medicine, 2041 Georgia Avenue Northwest, Suite 5C02, Washington, DC 20060, USA. Electronic address:

A variety of rheumatologic disorders may affect the liver. There is a significant epidemiologic, genetic, and immunologic overlap between immune-mediated rheumatologic disorders and autoimmune liver diseases. There is an increased frequency of autoimmune liver diseases, such as primary biliary cholangitis, autoimmune hepatitis, primary sclerosing cholangitis, or overlap syndrome, in patients with systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, systemic sclerosis, vasculitis, and other immune-related diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cld.2018.12.007DOI Listing
May 2019
7 Reads

A Case of Pancytopenia with Many Possible Causes: How Do You Tell Which is the Right One?

Eur J Case Rep Intern Med 2019 30;6(2):001012. Epub 2019 Jan 30.

Department of Internal Medicine, Cascais Hospital, Cascais, Portugal.

Systemic lupus erythematosus (SLE) often presents with cytopenia(s); however, pancytopenia is found less commonly, requiring the consideration of possible aetiologies other than the primary disease. The authors describe the case of a female patient with a recent diagnosis of SLE admitted through the Emergency Department with fever of unknown origin and severe pancytopenia. She was medicated with prednisolone, hydroxychloroquine, azathioprine, amlodipine and sildenafil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2019_001012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432823PMC
January 2019
11 Reads

Ustekinumab-induced subacute cutaneous lupus.

JAAD Case Rep 2019 Mar 1;5(3):271-273. Epub 2019 Mar 1.

Dermatology Department, University Hospital Limerick, Limerick, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.01.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403108PMC
March 2019
10 Reads

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.

Ann Rheum Dis 2019 04 4;78(4):504-508. Epub 2019 Feb 4.

AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Regional Pharmacovigilance Center, INSERM, Sorbonne Universités, Paris, France.

Objective: Drug-induced lupus (DIL) is an idiosyncratic side effect of treatments in which symptoms overlap with those of systemic lupus erythematosus (SLE). The spectrum of DIL constantly evolves with that of the pharmacopoeia. Here, we used VigiBase, the WHO global individual case safety reports (ICSRs) database, to identify the main drugs associated with DIL. Read More

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-21459
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2018-214598DOI Listing
April 2019
31 Reads

Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study.

J Am Acad Dermatol 2019 Aug 11;81(2):403-411. Epub 2019 Feb 11.

Department of Dermatology, Medical Science and Public Health, University of Cagliari, Cagliari, Italy; Task Force of Dermatopathology, European Academy of Dermatology and Venereology (EADV); SIDEMAST Dermatopathology Study Group, Italian Society of Dermatology.

Background: Clinical and pathologic criteria to distinguish drug-induced subacute lupus erythematosus (DI-SCLE) from idiopathic (I-SCLE) are controversial.

Objective: The aim of the survey was a retrospective analysis of a consistent number of iatrogenous and idiopathic SCLE cases, by means of clinical and histopathologic investigation.

Methods: Eleven European university dermatology units collected all diagnosed cases from January 2000 to December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.009DOI Listing
August 2019
17 Reads
4.449 Impact Factor

Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: An uncommon cause of drug-induced discoid lupus erythematosus.

Australas J Dermatol 2019 Aug 7;60(3):e208-e210. Epub 2019 Feb 7.

Department of Dermatology, Temple University Hospital, Philadelphia, Pennsylvania, USA.

Drug-induced chronic cutaneous lupus erythematosus, or drug-induced discoid lupus erythematosus, is a rare cutaneous phenomenon. Various medications have been associated with drug-induced discoid lupus erythematosus including fluorouracile agents, especially tegafur and uraciltegafur, and TNF-α antagonists such as infliximab or etanercept. Recent literature has described a case series of six patients receiving IgG immunoglobulin for chronic inflammatory demyelinating polyneuropathy with subsequent presentations of discoid lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12998DOI Listing
August 2019
9 Reads

[Etiologies and risk factors for young people with intracerebral hemorrhage].

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018 Nov;43(11):1246-1250

Department of Geriatrics Neurology, Xiangya Hospital, Central South University, Changsha 410008, China.

Objective: To determine the etiologies and risk factors of intracerebral hemorrhage in young people.
 Methods: A total of 401 young patients with intracerebral hemorrhage were enrolled, and they were assigned into a 20-29 , a 30-39, and a 40-45 age group. The differences of various etiologies and risk factors among the three groups were analyzed. Read More

View Article

Download full-text PDF

Source
http://www.csumed.org/xbwk/CN/10.11817/j.issn.1672-7347.2018
Publisher Site
http://dx.doi.org/10.11817/j.issn.1672-7347.2018.11.013DOI Listing
November 2018
44 Reads

Association of raised levels of IL-4 and anti-TPO with hyperprolactinemia.

Am J Reprod Immunol 2019 03 30;81(3):e13085. Epub 2019 Jan 30.

Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India.

Background And Objective: The modulatory role of prolactin in autoimmune regulation is well established. Hyperprolactinemia is often associated with autoimmune disease like systemic lupus erythematosus and autoimmune thyroid diseases. The objective was to compare levels of direct and indirect autoimmune factors in different categories of hyperprolactinemia cases and predict the direction of association between hyperprolactinemia and autoimmune factors, if any. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aji.13085DOI Listing
March 2019
17 Reads

When Chest Pain Reveals More: A Case of Hydrochlorothiazide-Induced Systemic Lupus Erythematosus.

Am J Case Rep 2019 Jan 7;20:26-30. Epub 2019 Jan 7.

Department of Internal Medicine, Trihealth Good Samaritan Hospital, Cincinnati, OH, USA.

BACKGROUND Drug induced lupus erythematosus is considered an autoimmune entity which is precipitated by medications. Hydrochlorothiazide has been recognized to cause subacute cutaneous lupus erythematosus, but very few cases of systemic drug induced lupus systemic erythematosus have been reported. CASE REPORT A 57-year-old Caucasian male with a past medical history of hypertension and hyperlipidemia presented with recurrent fevers, chest pain, and dyspnea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.911380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396705PMC
January 2019
10 Reads

INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids.

J Clin Exp Hepatol 2018 Dec 26;8(4):403-431. Epub 2018 Jun 26.

Hepatology & Liver Transplant (Medicine), Fortis Escorts Liver & Digestive Diseases Institute (FELDI), Fortis Escorts Hospital, Delhi, India.

Hepatitis B Virus (HBV) reactivation in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to HBV infection. These patients suffer a dual onslaught of illness: one from the primary disease for which they are receiving the culprit drug that led to HBV reactivation, and the other from HBV reactivation itself. The HBV reactivation not only leads to a compromised liver function, which may culminate into hepatic failure; it also adversely impacts the treatment outcome of the primary illness. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09736883183009
Publisher Site
http://dx.doi.org/10.1016/j.jceh.2018.06.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286881PMC
December 2018
87 Reads